CLOs on the Move

Armetheon

www.armetheon.com

 
Armetheon, Inc. is a privately held San Francisco Bay area-based biopharmaceutical company with late-stage clinical drug candidates in development for cardiovascular diseases. The company was founded in 2011 by experienced biotech entrepreneurs and drug developers. Armetheon’s two late-stage small molecule drug candidates are for use in the areas of oral anti-coagulation and anti-arrhythmia for atrial fibrillation. The company was founded with the idea that drug innovations can happen by building on the success of proven medications. We create solutions that are within the same class of medication and that utilize the same mechanism of action as existing therapies. This development approach has the ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.armetheon.com
  • 3375 Scott Blvd Suite 306
    Santa Clara, CA USA 95054
  • Phone: 650.646.3898

Executives

Name Title Contact Details

Similar Companies

Pelton Shepherd Industries

Pelton Shepherd Industries is a Stockton, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Amg Medical Inc

Amg Medical Inc is a Mont-Royal, QC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Medscope Communications

Medscope Communications, Inc. is a Saint-Laurent, QC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

White Plume

White Plume is a Birmingham, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Insulet

Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to making the lives of people with diabetes and other conditions easier through the use of its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet also leverages the unique design of its Pod, by tailoring its Omnpod technology platform for the delivery of non-insulin subcutaneous drugs across multiple therapeutic areas. Founded in 2000, more than 100,000 users across the globe rely on Insulet`s Omnipod Insulin Management System to bring simplicity and freedom to their lives. For more information, please visit: www.insulet.com, www.myomnipod.com and https://www.omnipodeurope.com.* *Starting July 1, 2018, Insulet will assume direct distribution of its Omnipod Insulin Management System in Europe, including sales, marketing, training and customer support activities. This will allow Insulet to be closer to the diabetes community and identify opportunities to support European customer needs over the long term, as it already does in the United States and Canada.